stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) P/S ratio
As of 5 November 2026, Beam Therapeutics Inc. (BEAM) trades at a P/S ratio of 18.6×. Over the past ten years it has ranged from 0.0× (March 2020) to 346,303× (July 2021); the current reading is higher than 23% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 19.6× | (38.95%) |
| FY2024 | 32.1× | 474.02% |
| FY2023 | 5.6× | (86.95%) |
| FY2022 | 42.9× | (56.55%) |
| FY2021 | 98.7× | (99.94%) |
| FY2020 | 158,971× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 17.5× | (23.93%) |
| Jun 2026 | 22.9× | 52.94% |
| Mar 2026 | 15.0× | (23.53%) |
| Dec 2025 | 19.6× | (56.10%) |
| 26 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| MBX MBX Biosciences, Inc. compare | n/m |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 5.7× |
| BEAM Beam Therapeutics Inc. | 18.6× |
| RCUS Arcus Biosciences, Inc. compare | 22.8× |
| XNCR Xencor, Inc. compare | 24.8× |
| IDYA IDEAYA Biosciences, Inc. compare | 86.7× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 91.1× |
| VRDN Viridian Therapeutics, Inc. compare | 118× |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement